Neveda Murugesan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Neveda Murugesan has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Damini Saxena
Baylor College of Medicine
2 shared publications - Muhammad Adrish
Baylor College of Medicine, Houston, TX, USA
2 shared publications - Arundhati Dileep
Division of Pulmonary & Critical Care Medicine, Bronx Care Health System, Bronx, NY 10457, USA
1 shared publication - Marina K. Ngassa
Baylor College of Medicine, Section of General Internal Medicine, 1 Baylor Plz, Houston, TX 77030, USA
1 shared publication - Nicola Alexander Hanania
Baylor College of Medicine, Houston, TX, USA
1 shared publication - Uyioghosa D. Evbayiro
Baylor College of Medicine, Section of General Internal Medicine, 1 Baylor Plz, Houston, TX 77030, USA
1 shared publication
Latest Publications
- Open Access
- 16 August 2024
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 14 (8) , 867
Inhalational Drug Devices: Revisiting the Linchpin of Asthma Management
Asthma remains a prevalent condition among all age groups globally. First-line treatment requires the delivery of medications into the distal respiratory tract via inhalers. Using appropriate inhaler techniques is a significant challenge in achieving disease control. A variety of inhalers are available for treating asthma, and selecting the appropriate inhaler type for any given patient is crucial to achieving and maintaining symptomatic control. This review will discuss the anatomy and physiology behind drug delivery via inhalers, the types of inhalers currently available for use, nebulizers, and future directions in the delivery of inhaled medications for asthma.
- 16 August 2024
- Published by MDPI AG in Journal of Personalized Medicine
- Vol. 14 (8) , 867
Open AccessInhalational Drug Devices: Revisiting the Linchpin of Asthma Management
Asthma remains a prevalent condition among all age groups globally. First-line treatment requires the delivery of medications into the distal respiratory tract via inhalers. Using appropriate inhaler techniques is a significant challenge in achieving disease control. A variety of inhalers are available for treating asthma, and selecting the appropriate inhaler type for any given patient is crucial to achieving and maintaining symptomatic control. This review will discuss the anatomy and physiology behind drug delivery via inhalers, the types of inhalers currently available for use, nebulizers, and future directions in the delivery of inhaled medications for asthma.
- Top Cited PapersOpen Access
- 15 April 2023
- Published by MDPI AG in Diagnostics
- Vol. 13 (8) , 1428
Update on the Role of FeNO in Asthma Management
Asthma is a heterogenous disorder characterized by presence of different phenotypes and endotypes. Up to 10% of the individuals suffer from severe asthma and are at increased risk of morbidity and mortality. Fractional exhaled nitric oxide (FeNO) is a cost-effective, point of care biomarker that is used to detect type 2 airway inflammation. Guidelines have proposed to measure FeNO as an adjunct to diagnostic evaluation in individuals with suspected asthma and to monitor airway inflammation. FeNO has lower sensitivity, suggesting that it may not be a good biomarker to rule out asthma. FeNO may also be used to predict response to inhaled corticosteroids, predict adherence and deciding on biologic therapy. Higher levels of FeNO have been associated with lower lung function and increased risk for future asthma exacerbations and its predictive value increases when combined with other standard measurements of asthma assessment.
- 15 April 2023
- Published by MDPI AG in Diagnostics
- Vol. 13 (8) , 1428
Top Cited PapersOpen AccessUpdate on the Role of FeNO in Asthma Management
Asthma is a heterogenous disorder characterized by presence of different phenotypes and endotypes. Up to 10% of the individuals suffer from severe asthma and are at increased risk of morbidity and mortality. Fractional exhaled nitric oxide (FeNO) is a cost-effective, point of care biomarker that is used to detect type 2 airway inflammation. Guidelines have proposed to measure FeNO as an adjunct to diagnostic evaluation in individuals with suspected asthma and to monitor airway inflammation. FeNO has lower sensitivity, suggesting that it may not be a good biomarker to rule out asthma. FeNO may also be used to predict response to inhaled corticosteroids, predict adherence and deciding on biologic therapy. Higher levels of FeNO have been associated with lower lung function and increased risk for future asthma exacerbations and its predictive value increases when combined with other standard measurements of asthma assessment.